Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Triple Negative Breast Cancer With and Without Intra-operative RT
NCT02977468Phase 1Completed
- Sponsor
- Columbia University
- Start
- Oct 2017
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Columbia University. Primary endpoint: Number of subjects with significant mean percent change in Tumor-Infiltrating Lymphocytes (TILs) at 3 months. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02977468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977468.